In Brief: Novartis Exelon
Executive Summary
Novartis Exelon: Company files NDA April 7 for treatment of Alzheimer's disease for the brain-selective acetylcholinase inhibitor. The application is based on Phase III trial results from 3,330 patients with mild to moderate Alzheimer's in trials using assessments rated by psychologists, clinicians and caregivers...